NasdaqGS:RVMDBiotechs
How Launching a Pivotal RAS G12D Pancreatic Cancer Trial At Revolution Medicines (RVMD) Has Changed Its Investment Story
Revolution Medicines has already begun treating patients in RASolute 305, a global, randomized Phase 3 trial testing zoldonrasib plus standard chemotherapy versus placebo plus chemotherapy as first-line treatment for metastatic RAS G12D pancreatic ductal adenocarcinoma, with primary endpoints of progression-free survival and overall survival.
This marks one of the first late-stage attempts to directly target the prevalent RAS G12D mutation, for which no approved targeted therapies currently...